Last updated on July 2019

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Brief description of study

Study AG348-C-006 will evaluate the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase deficiency (PKD), who are not regularly receiving blood transfusions. Participants will be randomized 1:1 to receive either AG-348 or matching placebo. The study is comprised of two parts. During the Part 1 Dose Optimization Period of the study, participants will start on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each participant's dose will be optimized individually, up to a maximum dose of 50 milligrams (mg), twice daily. During the Part 2 Fixed-Dose Period, participants will receive AG-348 at their optimized dose from Part 1.

Clinical Study Identifier: NCT03548220

Find a site near you

Start Over

Stanford University

Palo Alto, CA United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Duke University

Durham, NC United States
  Connect »

H pital de la Timone

Marseille, Cedex 5, France
  Connect »

Yeungnam University Hospital

Daegu 705-703, Korea, Republic of
  Connect »

Yeungnam University Hospital

Gyeongsang, Korea, Republic of
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Manchester Royal Infirmary

Manchester, United Kingdom
  Connect »

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.